News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Laboratories (ABT) Declines Option For Speedel Pharmaceuticals, Inc. Drug



8/17/2006 8:33:02 AM

Abbott Laboratories has decided not to exercise its license-back option for Speedel's SPP200 which has recently completed a successful phase II trial in patients undergoing chronic haemodialysis.

>>> Discuss This Story



Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES